Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Fly Intel: Pre-market Movers » 09:03
06/22/20
06/22
09:03
06/22/20
09:03
SPCE

Virgin Galactic

$14.98 /

-0.22 (-1.45%)

, EVOK

Evoke Pharma

$2.35 /

+0.07 (+3.07%)

, PCG

PG&E

$10.24 /

-0.585 (-5.41%)

, MYO

Myomo

$3.80 /

-0.05 (-1.30%)

, EVLO

Evelo Biosciences

$3.82 /

+0.17 (+4.66%)

, AAL

American Airlines

$16.00 /

-0.485 (-2.94%)

, TSN

Tyson Foods

$63.23 /

-0.75 (-1.17%)

, LK

Luckin Coffee

$3.82 /

-0.14 (-3.54%)

, NBRV

Nabriva Therapeutics

$0.81 /

-0.0554 (-6.37%)

Check out this morning's…

Open Full Text

ShowHide Related Items >><<
TSN Tyson Foods
$63.23 /

-0.75 (-1.17%)

SPCE Virgin Galactic
$14.98 /

-0.22 (-1.45%)

PCG PG&E
$10.24 /

-0.585 (-5.41%)

NBRV Nabriva Therapeutics
$0.81 /

-0.0554 (-6.37%)

MYO Myomo
$3.80 /

-0.05 (-1.30%)

LK Luckin Coffee
$3.82 /

-0.14 (-3.54%)

EVOK Evoke Pharma
$2.35 /

+0.07 (+3.07%)

EVLO Evelo Biosciences
$3.82 /

+0.17 (+4.66%)

AAL American Airlines
$16.00 /

-0.485 (-2.94%)

SPCE Virgin Galactic
$14.98 /

-0.22 (-1.45%)

03/24/20 Morgan Stanley
Morgan Stanley upgrades Virgin Galactic to Overweight after over 70% drop
03/24/20 Morgan Stanley
Virgin Galactic upgraded to Overweight from Equal Weight at Morgan Stanley
03/03/20 Morgan Stanley
Lead up to next lunar landings can have 'powerful impact,' says Morgan Stanley
02/27/20
Fly Intel: Top five analyst downgrades
EVOK Evoke Pharma
$2.35 /

+0.07 (+3.07%)

06/22/20 H.C. Wainwright
Evoke Pharma upgraded to Buy from Neutral at H.C. Wainwright
PCG PG&E
$10.24 /

-0.585 (-5.41%)

06/10/20 Barclays
PG&E price target raised to $16 from $15 at Barclays
06/09/20 Morgan Stanley
PG&E updated financing plan offers less downside risk, says Morgan Stanley
06/09/20 Mizuho
PG&E price target raised to $14.50 from $13.50 at Mizuho
06/05/20 BofA
PG&E resumed with a Buy at BofA
MYO Myomo
$3.80 /

-0.05 (-1.30%)

05/27/20
Myomo initiated with a Buy at Dougherty
03/23/20 Ascendiant
Myomo price target lowered to $15 from $45 at Ascendiant
11/14/19
Fly Intel: Top five analyst downgrades
11/14/19 Roth Capital
Roth Capital downgrades Myomo to Neutral, cuts target to 55c
EVLO Evelo Biosciences
$3.82 /

+0.17 (+4.66%)

05/21/20 Morgan Stanley
Morgan Stanley downgrades Evelo to Equal Weight after AD discontinuation
05/21/20 Morgan Stanley
Evelo Biosciences downgraded to Equal Weight from Overweight at Morgan Stanley
05/12/20 Jefferies
Evelo Biosciences downgraded to Hold from Buy at Jefferies
AAL American Airlines
$16.00 /

-0.485 (-2.94%)

06/17/20
Fly Intel: Top five analyst initiations
06/17/20 Seaport Global
American Airlines initiated with a Buy at Seaport Global
06/17/20 Cowen
American Airlines price target raised to $20 from $15 at Cowen
06/16/20 Stifel
United loyalty deal raises odds of survival without restructuring, says Stifel
TSN Tyson Foods
$63.23 /

-0.75 (-1.17%)

06/10/20 Credit Suisse
Tyson Foods price target raised to $75 from $70 at Credit Suisse
06/04/20
Fly Intel: Top five analyst upgrades
06/04/20 BofA
BofA cuts Pilgrim's Pride, Sanderson Farms targets after price fixing indictment
06/04/20 Bernstein
Tyson Foods upgraded to Outperform with $83 target at Bernstein
LK Luckin Coffee
$3.82 /

-0.14 (-3.54%)

04/08/20 GLJ Research
JinkoSolar price target lowered to $6.88 from $7.97 at GLJ Research
04/08/20 UBS
Starbucks price target lowered to $73 from $95 at UBS
04/06/20 MKM Partners
Starbucks price target raised to $60 from $52 at MKM Partners
04/02/20 KeyBanc
KeyBanc cuts Luckin Coffee to Sector Weight as company probes fake transactions
NBRV Nabriva Therapeutics
$0.81 /

-0.0554 (-6.37%)

06/22/20 Northland
Nabriva Therapeutics price target lowered to $1.50 from $2.50 at Northland
04/23/20 Northland
Nabriva Therapeutics price target lowered to $2.50 from $5 at Northland
04/09/20 H.C. Wainwright
Nabriva Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
04/08/20 Needham
Nabriva Therapeutics downgraded to Hold from Buy at Needham
TSN Tyson Foods
$63.23 /

-0.75 (-1.17%)

SPCE Virgin Galactic
$14.98 /

-0.22 (-1.45%)

PCG PG&E
$10.24 /

-0.585 (-5.41%)

NBRV Nabriva Therapeutics
$0.81 /

-0.0554 (-6.37%)

MYO Myomo
$3.80 /

-0.05 (-1.30%)

EVOK Evoke Pharma
$2.35 /

+0.07 (+3.07%)

EVLO Evelo Biosciences
$3.82 /

+0.17 (+4.66%)

AAL American Airlines
$16.00 /

-0.485 (-2.94%)

  • 23
    Jun
TSN Tyson Foods
$63.23 /

-0.75 (-1.17%)

SPCE Virgin Galactic
$14.98 /

-0.22 (-1.45%)

PCG PG&E
$10.24 /

-0.585 (-5.41%)

LK Luckin Coffee
$3.82 /

-0.14 (-3.54%)

AAL American Airlines
$16.00 /

-0.485 (-2.94%)

TSN Tyson Foods
$63.23 /

-0.75 (-1.17%)

SPCE Virgin Galactic
$14.98 /

-0.22 (-1.45%)

PCG PG&E
$10.24 /

-0.585 (-5.41%)

LK Luckin Coffee
$3.82 /

-0.14 (-3.54%)

EVLO Evelo Biosciences
$3.82 /

+0.17 (+4.66%)

AAL American Airlines
$16.00 /

-0.485 (-2.94%)

TSN Tyson Foods
$63.23 /

-0.75 (-1.17%)

SPCE Virgin Galactic
$14.98 /

-0.22 (-1.45%)

PCG PG&E
$10.24 /

-0.585 (-5.41%)

NBRV Nabriva Therapeutics
$0.81 /

-0.0554 (-6.37%)

LK Luckin Coffee
$3.82 /

-0.14 (-3.54%)

AAL American Airlines
$16.00 /

-0.485 (-2.94%)

Recommendations
Nabriva Therapeutics price target lowered to $1.50 from $2.50 at Northland » 07:45
06/22/20
06/22
07:45
06/22/20
07:45
NBRV

Nabriva Therapeutics

$0.81 /

-0.0554 (-6.37%)

Northland analyst Carl…

Northland analyst Carl Byrnes lowered the firm's price target on Nabriva Therapeutics to $1.50 from $2.50 and keeps an Outperform rating on the shares after the company received a Complete Response Letter, or CRL, for CONTEPO as the FDA was unable to complete observations at the company's manufacturing partners due to travel restrictions. While calling this news a setback, Byrnes said he anticipates visibility into the timing of an NDA resubmission late in the third quarter.

ShowHide Related Items >><<
NBRV Nabriva Therapeutics
$0.81 /

-0.0554 (-6.37%)

NBRV Nabriva Therapeutics
$0.81 /

-0.0554 (-6.37%)

04/23/20 Northland
Nabriva Therapeutics price target lowered to $2.50 from $5 at Northland
04/09/20 H.C. Wainwright
Nabriva Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
04/08/20 Needham
Nabriva Therapeutics downgraded to Hold from Buy at Needham
03/24/20 H.C. Wainwright
Paratek, Nabriva can benefit from DISARM Act passage, says H.C. Wainwright
NBRV Nabriva Therapeutics
$0.81 /

-0.0554 (-6.37%)

NBRV Nabriva Therapeutics
$0.81 /

-0.0554 (-6.37%)

Hot Stocks
Nabriva Therapeutics receives CRL from FDA on NDA for CONTEPO for injection » 15:21
06/21/20
06/21
15:21
06/21/20
15:21
NBRV

Nabriva Therapeutics

$0.81 /

-0.0554 (-6.37%)

Nabriva Therapeutics…

Nabriva Therapeutics announced that it received a Complete Response Letter from the U.S. Food and Drug Administration for the New Drug Application resubmission seeking marketing approval of CONTEPO for injection for the treatment of complicated urinary tract infections, including acute pyelonephritis. The company said that although Nabriva's European contract manufacturing partners were prepared for regulatory authority inspections, the CRL cites observations at the company's manufacturing partners that could not be resolved due to FDA's inability to conduct onsite inspections because of travel restrictions. In general, previously identified product quality and facility inspection related observations at its contract manufacturing partners are required to be satisfactorily resolved before the NDA may be approved. The FDA did not request any new clinical data and did not raise any other concerns with regard to the safety or efficacy of CONTEPO in the CRL. Nabriva plans to request a Type A meeting with the FDA to discuss appropriate next steps and the FDA's plans for completing foreign facility inspections. CONTEPO has been granted Qualified Infectious Disease Product and Fast Track designations by the FDA for the treatment of serious infections, including cUTI.

ShowHide Related Items >><<
NBRV Nabriva Therapeutics
$0.81 /

-0.0554 (-6.37%)

NBRV Nabriva Therapeutics
$0.81 /

-0.0554 (-6.37%)

04/23/20 Northland
Nabriva Therapeutics price target lowered to $2.50 from $5 at Northland
04/09/20 H.C. Wainwright
Nabriva Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
04/08/20 Needham
Nabriva Therapeutics downgraded to Hold from Buy at Needham
03/24/20 H.C. Wainwright
Paratek, Nabriva can benefit from DISARM Act passage, says H.C. Wainwright
NBRV Nabriva Therapeutics
$0.81 /

-0.0554 (-6.37%)

NBRV Nabriva Therapeutics
$0.81 /

-0.0554 (-6.37%)

Conference/Events
FDA PDUFA Date for Nabriva Therapeutics CONTEPO (Fosfomycin) is June 19, 2020  08:03
06/19/20
06/19
08:03
06/19/20
08:03
NBRV

Nabriva Therapeutics

$0.87 /

-0.037 (-4.08%)

 
ShowHide Related Items >><<
NBRV Nabriva Therapeutics
$0.87 /

-0.037 (-4.08%)

NBRV Nabriva Therapeutics
$0.87 /

-0.037 (-4.08%)

04/23/20 Northland
Nabriva Therapeutics price target lowered to $2.50 from $5 at Northland
04/09/20 H.C. Wainwright
Nabriva Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
04/08/20 Needham
Nabriva Therapeutics downgraded to Hold from Buy at Needham
03/24/20 H.C. Wainwright
Paratek, Nabriva can benefit from DISARM Act passage, says H.C. Wainwright
NBRV Nabriva Therapeutics
$0.87 /

-0.037 (-4.08%)

NBRV Nabriva Therapeutics
$0.87 /

-0.037 (-4.08%)

Options
Largest borrow rate increases among liquid names » 08:45
06/17/20
06/17
08:45
06/17/20
08:45
MARK

Remark Holdings

$2.66 /

+0.42 (+18.79%)

, DNR

Denbury Resources

$0.47 /

+0.0238 (+5.37%)

, EURN

Euronav NV

$8.85 /

-0.295 (-3.23%)

, SSYS

Stratasys

$17.25 /

+0.04 (+0.23%)

, MAC

Macerich

$9.62 /

+0.05 (+0.52%)

, SRNE

Sorrento Therapeutics

$4.89 /

+0.01 (+0.21%)

, BGS

B&G Foods

$24.33 /

+0.04 (+0.16%)

, SAND

Sandstorm Gold

$8.24 /

-0.16 (-1.90%)

, NBRV

Nabriva Therapeutics

$0.96 /

+0.0696 (+7.78%)

, EOLS

Evolus

$5.25 /

+0.17 (+3.35%)

Latest data shows the…

Latest data shows the largest indicative borrow rate increases among liquid option names include: Remark Media (MARK) 125.48% +8.28, Denbury Resources (DNR) 36.99% +2.03, Euronav NV (EURN) 22.48% +1.38, Stratasys (SSYS) 6.53% +1.16, Macerich (MAC) 7.26% +0.80, Sorrento Therapeutics (SRNE) 34.21% +0.66, B&G Foods (BGS) 1.95% +0.65, Sandstorm Gold (SAND) 1.56% +0.49, Nabriva Therapeutics (NBRV) 7.22% +0.40, and Evolus (EOLS) 21.76% +0.38.

ShowHide Related Items >><<
SSYS Stratasys
$17.25 /

+0.04 (+0.23%)

SRNE Sorrento Therapeutics
$4.89 /

+0.01 (+0.21%)

SAND Sandstorm Gold
$8.24 /

-0.16 (-1.90%)

NBRV Nabriva Therapeutics
$0.96 /

+0.0696 (+7.78%)

MARK Remark Holdings
$2.66 /

+0.42 (+18.79%)

MAC Macerich
$9.62 /

+0.05 (+0.52%)

EURN Euronav NV
$8.85 /

-0.295 (-3.23%)

EOLS Evolus
$5.25 /

+0.17 (+3.35%)

DNR Denbury Resources
$0.47 /

+0.0238 (+5.37%)

BGS B&G Foods
$24.33 /

+0.04 (+0.16%)

MARK Remark Holdings
$2.66 /

+0.42 (+18.79%)

06/10/20 Roth Capital
Roth checks point to Kent Services as Remark Holdings distribution partner
05/27/20 Roth Capital
Wynn video 'clearly shows' Remark AI technology in use, says Roth Capital
07/15/19 Roth Capital
Sharecare liquidity event would help capitalize Remark AI business, says Roth Capital
DNR Denbury Resources
$0.47 /

+0.0238 (+5.37%)

03/31/20 Stifel
Denbury Resources downgraded to Sell from Hold at Stifel
03/20/20 Stephens
Stephens upgrades Hess, downgrades 11 others in E&P following oil's melt down
03/20/20 Stephens
Denbury Resources downgraded to Underweight from Equal Weight at Stephens
EURN Euronav NV
$8.85 /

-0.295 (-3.23%)

06/02/20 Fearnley
Euronav NV downgraded to Hold from Buy at Fearnley
05/28/20 DNB Markets
Euronav NV upgraded to Buy from Hold at DNB Markets
03/09/20 DNB Markets
Euronav NV downgraded to Hold from Buy at DNB Markets
01/09/20 Deutsche Bank
Deutsche Bank adds Euronav NV as 'Catalyst Call Buy'
SSYS Stratasys
$17.25 /

+0.04 (+0.23%)

06/03/20 Craig-Hallum
Stratasys price target raised to $20 from $15 at Craig-Hallum
06/02/20 JPMorgan
Stratasys upgraded to Overweight after 'overdue' cost cutting at JPMorgan
06/02/20 JPMorgan
Stratasys upgraded to Overweight from Neutral at JPMorgan
05/21/20 JPMorgan
Stratasys upgraded to Neutral with $19 price target at JPMorgan
MAC Macerich
$9.62 /

+0.05 (+0.52%)

06/15/20 Evercore ISI
Macerich downgraded to Underperform from In Line at Evercore ISI
06/04/20 Compass Point
Compass Point starts Macerich with Neutral, $9 price target
06/04/20 Compass Point
Macerich initiated with a Neutral at Compass Point
05/29/20 RBC Capital
Macerich price target lowered to $10 from $34 at RBC Capital
SRNE Sorrento Therapeutics
$4.89 /

+0.01 (+0.21%)

05/26/20 Dawson James
Sorrento Therapeutics initiated with a Buy at Dawson James
10/07/19 JMP Securities
Sorrento Therapeutics initiated with an Outperform at JMP Securities
07/23/19 H.C. Wainwright
Sorrento Therapeutics price target lowered to $30 from $40 at H.C. Wainwright
BGS B&G Foods
$24.33 /

+0.04 (+0.16%)

06/12/20
Fly Intel: Top five analyst initiations
06/11/20 DA Davidson
B&G Foods initiated with a Neutral at DA Davidson
06/11/20 RBC Capital
B&G Foods initiated with a Sector Perform at RBC Capital
05/13/20
Fly Intel: Top five analyst upgrades
SAND Sandstorm Gold
$8.24 /

-0.16 (-1.90%)

05/08/20 TD Securities
Sandstorm Gold downgraded to Hold from Buy at TD Securities
10/31/19 CIBC
Sandstorm Gold upgraded to Outperformer from Neutral at CIBC
NBRV Nabriva Therapeutics
$0.96 /

+0.0696 (+7.78%)

04/23/20 Northland
Nabriva Therapeutics price target lowered to $2.50 from $5 at Northland
04/09/20 H.C. Wainwright
Nabriva Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
04/08/20 Needham
Nabriva Therapeutics downgraded to Hold from Buy at Needham
03/24/20 H.C. Wainwright
Paratek, Nabriva can benefit from DISARM Act passage, says H.C. Wainwright
EOLS Evolus
$5.25 /

+0.17 (+3.35%)

06/02/20 Mizuho
Evolus fundamentals unchanged despite ITC delay, says Mizuho
05/26/20 Mizuho
Evolus rally Friday has no clear explanation, says Mizuho
05/22/20 Barclays
News from Korea on Medytox has 'no implications' for Evolus, says Barclays
05/22/20 Cantor Fitzgerald
Evolus stock move likely good news, says Cantor Fitzgerald
SSYS Stratasys
$17.25 /

+0.04 (+0.23%)

SAND Sandstorm Gold
$8.24 /

-0.16 (-1.90%)

NBRV Nabriva Therapeutics
$0.96 /

+0.0696 (+7.78%)

MAC Macerich
$9.62 /

+0.05 (+0.52%)

EOLS Evolus
$5.25 /

+0.17 (+3.35%)

DNR Denbury Resources
$0.47 /

+0.0238 (+5.37%)

BGS B&G Foods
$24.33 /

+0.04 (+0.16%)

SRNE Sorrento Therapeutics
$4.89 /

+0.01 (+0.21%)

MAC Macerich
$9.62 /

+0.05 (+0.52%)

EURN Euronav NV
$8.85 /

-0.295 (-3.23%)

DNR Denbury Resources
$0.47 /

+0.0238 (+5.37%)

SSYS Stratasys
$17.25 /

+0.04 (+0.23%)

SRNE Sorrento Therapeutics
$4.89 /

+0.01 (+0.21%)

MARK Remark Holdings
$2.66 /

+0.42 (+18.79%)

BGS B&G Foods
$24.33 /

+0.04 (+0.16%)

MAC Macerich
$9.62 /

+0.05 (+0.52%)

SSYS Stratasys
$17.25 /

+0.04 (+0.23%)

SRNE Sorrento Therapeutics
$4.89 /

+0.01 (+0.21%)

SAND Sandstorm Gold
$8.24 /

-0.16 (-1.90%)

MARK Remark Holdings
$2.66 /

+0.42 (+18.79%)

MAC Macerich
$9.62 /

+0.05 (+0.52%)

EURN Euronav NV
$8.85 /

-0.295 (-3.23%)

DNR Denbury Resources
$0.47 /

+0.0238 (+5.37%)

BGS B&G Foods
$24.33 /

+0.04 (+0.16%)

Over a month ago
Syndicate
Nabriva Therapeutics announces $38M at-the-market registered direct offering » 06:36
06/01/20
06/01
06:36
06/01/20
06:36
NBRV

Nabriva Therapeutics

$1.14 /

+0.2869 (+33.63%)

Nabriva Therapeutics…

Nabriva Therapeutics announced that it has entered into a definitive agreement with several healthcare-focused institutional investors, including Fidelity Management & Research Company, LLC, for the purchase and sale of an aggregate of 41,445,373 ordinary shares and warrants to purchase up to an aggregate of 41,445,373 ordinary shares in a registered direct offering priced at-the-market under Nasdaq rules. Each ordinary share and accompanying warrant are being sold together at a combined purchase price of $0.91686. The warrants have an exercise price of $0.792 per share, are exercisable on the issuance date and will expire on the two-year anniversary of the issuance date. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

ShowHide Related Items >><<
NBRV Nabriva Therapeutics
$1.14 /

+0.2869 (+33.63%)

NBRV Nabriva Therapeutics
$1.14 /

+0.2869 (+33.63%)

04/23/20 Northland
Nabriva Therapeutics price target lowered to $2.50 from $5 at Northland
04/09/20 H.C. Wainwright
Nabriva Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
04/08/20 Needham
Nabriva Therapeutics downgraded to Hold from Buy at Needham
03/24/20 H.C. Wainwright
Paratek, Nabriva can benefit from DISARM Act passage, says H.C. Wainwright
NBRV Nabriva Therapeutics
$1.14 /

+0.2869 (+33.63%)

Hot Stocks
Nabriva gets 'positive' EU CHMP opinion for Xenleta for CAP treatment » 08:31
05/29/20
05/29
08:31
05/29/20
08:31
NBRV

Nabriva Therapeutics

$0.85 /

+0.0063 (+0.74%)

Nabriva Therapeutics…

Nabriva Therapeutics announced that the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA, has adopted a positive opinion recommending approval of XENLETA, lefamulin, for the treatment of community-acquired pneumonia, CAP, in adults when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of CAP or when these have failed. The CHMP opinion will be reviewed by the European Commission (EC), which has the authority to approve medicines for all 28 countries of the European Union, Norway, Iceland, and Liechtenstein. A regulatory decision is anticipated during the second half of 2020. "Today's announcement brings us one step closer to the first approval of a new class of antibiotics for patients with community-acquired pneumonia in Europe in almost 20 years," said Jennifer Schranz, MD, Chief Medical Officer of Nabriva. "XENLETA has a novel mechanism of action and provides an urgently needed short course, empiric monotherapy treatment alternative for adult patients with CAP. We look forward to the European Commission's decision and the opportunity to bring this important medicine to patients." The CHMP recommendation for marketing authorization is based on efficacy data from the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 studies and a safety database of 1,242 study participants.

ShowHide Related Items >><<
NBRV Nabriva Therapeutics
$0.85 /

+0.0063 (+0.74%)

NBRV Nabriva Therapeutics
$0.85 /

+0.0063 (+0.74%)

04/23/20 Northland
Nabriva Therapeutics price target lowered to $2.50 from $5 at Northland
04/09/20 H.C. Wainwright
Nabriva Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
04/08/20 Needham
Nabriva Therapeutics downgraded to Hold from Buy at Needham
03/24/20 H.C. Wainwright
Paratek, Nabriva can benefit from DISARM Act passage, says H.C. Wainwright
NBRV Nabriva Therapeutics
$0.85 /

+0.0063 (+0.74%)

Hot Stocks
Nabriva Therapeutics announces publication of study on S. pneumoniae » 08:16
05/18/20
05/18
08:16
05/18/20
08:16
NBRV

Nabriva Therapeutics

$0.57 /

+0.0404 (+7.62%)

Nabriva Therapeutics…

Nabriva Therapeutics announced the publication of a study entitled, A Multicenter Evaluation of the U.S. Prevalence and Regional Variation in Macrolide Resistant S. pneumoniae from Blood or Respiratory Cultures among Adult Patients, online in the proceedings of 30th European Congress on Clinical Microbiology and Infectious Diseases. This study assessed 3,510 patients with a positive S. pneumoniae blood or respiratory culture in the ambulatory and inpatient setting at 329 hospitals across nine U.S. Census geographic regions over 12 months ending 3Q2019 to determine the prevalence and rates of macrolide resistance in S. pneumoniae. Macrolide resistance was observed in 47.3 percent of S. pneumoniae obtained from respiratory cultures, and 29.6 percent from blood cultures. Higher rates of macrolide resistance were seen among ambulatory patients (45.3 percent) as compared with inpatients. While the overall rate of macrolide resistance was 39.5 percent, regional variation occurred, ranging from 13.9 percent in the Mountain region to 54.2 percent in the West North Central region, demonstrating the importance of local epidemiology data to inform selection of empiric therapy for patients with community-acquired bacterial pneumonia. S. pneumoniae is the leading cause of community-acquired bacterial pneumonia, a lung infection and the most common type of pneumonia that occurs outside of hospitals or other health care facilities. In its 2019 Antibiotic Threats Report, the Centers for Disease Control and Prevention designated macrolide-resistant S. pneumoniae as a "Serious Threat" to patients. According to the CDC, S. pneumoniae causes 900,000 infections and 3,600 deaths annually. Joint guidelines issued by the Infectious Disease Society of America and the American Thoracic Society for the treatment of CABP recommend macrolide antibiotics only be used in geographical regions where outpatient macrolide resistance is less than 25 percent. XENLETA is a systemic pleuromutilin antibiotic for the intravenous and oral treatment of CABP in adults. XENLETA offers an effective and well tolerated empiric monotherapy for CABP with a treatment duration as short as five days and the potential to address the limitations of existing agents. XENLETA has a novel mechanism of action that targets a binding site on bacteria that is different from existing antibiotics. It has been shown to result in no cross resistance to other antibiotic classes commonly prescribed for CABP and a low potential for the development of resistance. XENLETA is also convenient for patients being treated in the hospital, transitioning treatment out of the hospital or initiating treatment in the community.

ShowHide Related Items >><<
NBRV Nabriva Therapeutics
$0.57 /

+0.0404 (+7.62%)

NBRV Nabriva Therapeutics
$0.57 /

+0.0404 (+7.62%)

04/23/20 Northland
Nabriva Therapeutics price target lowered to $2.50 from $5 at Northland
04/09/20 H.C. Wainwright
Nabriva Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
04/08/20 Needham
Nabriva Therapeutics downgraded to Hold from Buy at Needham
03/24/20 H.C. Wainwright
Paratek, Nabriva can benefit from DISARM Act passage, says H.C. Wainwright
NBRV Nabriva Therapeutics
$0.57 /

+0.0404 (+7.62%)

Earnings
Nabriva Therapeutics reports Q1 EPS (25c), consensus (26c) » 16:15
05/11/20
05/11
16:15
05/11/20
16:15
NBRV

Nabriva Therapeutics

$0.73 /

+0.1183 (+19.40%)

Reports Q1 revenue $789K,…

Reports Q1 revenue $789K, consensus $460K

ShowHide Related Items >><<
NBRV Nabriva Therapeutics
$0.73 /

+0.1183 (+19.40%)

04/23/20 Northland
Nabriva Therapeutics price target lowered to $2.50 from $5 at Northland
04/09/20 H.C. Wainwright
Nabriva Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
04/08/20 Needham
Nabriva Therapeutics downgraded to Hold from Buy at Needham
03/24/20 H.C. Wainwright
Paratek, Nabriva can benefit from DISARM Act passage, says H.C. Wainwright
Hot Stocks
Nabriva announces publication of results from analysis of lefamulin data » 07:43
05/05/20
05/05
07:43
05/05/20
07:43
NBRV

Nabriva Therapeutics

$0.55 /

+0.0247 (+4.66%)

Nabriva Therapeutics…

Nabriva Therapeutics announced that Open Forum Infectious Diseases, an official journal of the Infectious Diseases Society of America, has published results from a post-hoc analysis of clinical data from patients who initiated treatment in the hospital from the pivotal Lefamulin Evaluation Against Pneumonia 1 and LEAP 2 Phase 3 clinical trials. The analyses indicate that lefamulin results in a rapid and similar time to clinical response, a proxy for hospital "discharge readiness," compared to moxifloxacin. In the post-hoc analysis, investigators examined pooled data of 926 inpatients from the LEAP trials; 468 patients were treated with lefamulin and 458 were treated with moxifloxacin. The analysis evaluated three outcomes among the study population: time to clinical response, time to clinical stability, and time to clinical improvement. Of the 926 patients included, investigators were able to assess time to clinical response in 918, clinical stability in 925, and clinical improvement in 923. Analyses demonstrated that time to clinical response was nearly identical in both treatment groups, with a median time from treatment initiation to clinical response of 4 days for lefamulin and 4 days for moxifloxacin. The median time from treatment initiation to clinical stability or clinical improvement was 3 days in both the lefamulin and moxifloxacin groups. Given the association between time to clinical response and readiness for hospital discharge in patients with CABP, the findings support the potential of lefamulin as an effective IV and oral short-course, monotherapy for CABP that may enable early discharge. XENLETA is a pleuromutilin antibiotic approved by the U.S. Food and Drug Administration for the treatment of community-acquired bacterial pneumonia. It is available in IV and oral formulations enabling initiation of treatment in the hospital, transitioning to outpatient setting or initiating treatment in the community. XENLETA has a novel mechanism of action that targets a binding site on bacteria that is different from existing antibiotics which has been shown to result in no cross resistance to other antibiotic classes commonly prescribed for CABP and a low potential for the development of resistance. Full results of the post-hoc analysis of LEAP trials data is included in the paper titled: Post Hoc Assessment of Time to Clinical Response Among Adults Hospitalized with Community-Acquired Bacterial Pneumonia Who Received Either Lefamulin or Moxifloxacin in Two Phase III Randomized, Double-Blind, Double-Dummy Clinical Trials, published in Open Forum Infectious Diseases, April 24, 2020.

ShowHide Related Items >><<
NBRV Nabriva Therapeutics
$0.55 /

+0.0247 (+4.66%)

04/23/20 Northland
Nabriva Therapeutics price target lowered to $2.50 from $5 at Northland
04/09/20 H.C. Wainwright
Nabriva Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
04/08/20 Needham
Nabriva Therapeutics downgraded to Hold from Buy at Needham
03/24/20 H.C. Wainwright
Paratek, Nabriva can benefit from DISARM Act passage, says H.C. Wainwright

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.